Drug Discovery@nature.com 3 January 2014

If you are unable to see the message below, click here to view.

TABLE OF CONTENTS 3 January 2014 News Analysis Research Highlights Research & Reviews Careers Nature Reviews Drug Discovery is on Twitter Advertisement Nature Collections TCGA pan-cancer analysis The Cancer Genome Atlas Pan-cancer initiative examines the similarities and differences among the genomic and cellular alterations found in the first dozen tumor types to be profiled by TCGA. This first look across cancer offers new tools in genomics and bioinformatics and the prospect of repurposing targeted therapies directed by the molecular pathology of the tumors in addition to their clinical classification. Access the Collection and accompanying Podcast, FREE at:  ww.nature.com/tcga   Produced with support from  Illumina    News Top 2013 in reflection doi:10.1038/nrd4218 Clinical trial data transparency, an IPO surge and more made the news last year. Full Text EMA's parallel advice workshop bridges regulatory and reimbursement divide doi:10.1038/nrd4219 Regulators and health technology assessment bodies discussed early experiences with pilot programmes in which they work together to provide drug developers with joint advice on the design of clinical trials. Full Text Market watch: Are orphan drug companies the pick of the pharmaceutical industry? doi:10.1038/nrd4205 This analysis, using multiple financial indicators, suggests that orphan drug companies have not been performing as strongly relative to other companies in recent years, as commonly perceived. Full Text Market watch: Upcoming market catalysts in Q1 2014 doi:10.1038/nrd4206 Notable market catalysts for the first quarter of 2014 include a US FDA advisory panel meeting for fluocinolone acetonide for diabetic macular oedema, and an FDA approval decision for elosulfase alfa, a treatment for mucopolysaccharidosis IV. Full Text Analysis Top Oral nanoparticles doi:10.1038/scibx.2013.1371 A US research team has developed targeted nanoparticles that could enable the oral delivery of biologics. Translation of the approach will require identifying a suitable therapeutic payload and fine-tuning the pharmacology of the system. Full Text UK academic drug discovery doi:10.1038/nrd4200 This article presents a survey of the academic drug discovery environment in the United Kingdom in 2013, and discusses the major trends in comparison with the United States. Full Text Research Highlights Top Viral diseases: Zeroing in on RSV vaccine design doi:10.1038/nrd4207 Structure-based design produces a novel vaccine for respiratory syncytial virus, which shows a high level of neutralizing activity in mice and rhesus macaques. Full Text Antibacterial drugs: Persisters come under fire doi:10.1038/nrd4215 Two studies report novel approaches to eradicate bacterial persisters, which complicate the treatment of chronic infections as they are recalcitrant to killing by antibiotics. Full Text Malaria: A step closer to elimination? doi:10.1038/nrd4216 A group of scientists from academia and industry report the discovery of a new class of antimalarials with promising preventive, therapeutic and transmission-blocking activity. Full Text Research & Reviews Top Therapeutic targeting of EPH receptors and their ligands doi:10.1038/nrd4175 EPH receptor (EPH)–ephrin signalling has crucial roles in embryonic development, as well as in adult tissue and organ maintenance, regeneration and pathogenesis. This article discusses the potential and limitations of targeting EPH–ephrin function in the treatment of disorders including cancer, neurological diseases and inflammation. Full Text The two faces of Hippo: targeting the Hippo pathway for regenerative medicine and cancer treatment doi:10.1038/nrd4161 The Hippo signalling pathway is an emerging growth control pathway with roles in organ growth control, stem cell function, regeneration and tumour suppression. This article reviews the regulation and functions of the Hippo signalling pathway, focusing on its potential to be therapeutically targeted in the treatment of cancer as well as tissue repair and regeneration following injury. Full Text Tetraspanin proteins promote multiple cancer stages doi:10.1038/nrc3640 This Review discusses recent evidence, particularly from mouse models, showing that some tetraspanin proteins have important roles in tumour initiation, promotion, metastasis and angiogenesis, and that they might therefore be valid therapeutic targets. Full Text Ribosome-targeting antibiotics and mechanisms of bacterial resistance doi:10.1038/nrmicro3155 The ribosome is one of the primary antibiotic targets in the bacterial cell. This review discusses how high-resolution crystal structures of antibiotic–ribosome complexes have provided molecular insight into the mechanisms of antibiotic action and bacterial resistance, in addition to the approaches being pursued for the development of improved and novel ribosome-targeting antibiotics. Full Text Drug Discovery JOBS of the week Development of novel treatment for drug-resistant leukemia Oslo University Hospital Post-doctoral Position in Drug Discovery Inserm (French Institute of Health and Medical Research) Environmental Microbiologist & Environmental Organic Bio-chemist Ben Gurion University of the Negev Bernal Chair in Biomedical Engineering - Multiannual University of Limerick Postdoctoral Fellow in Biomedical Engineering Queensland University of Technology - Translational Research Institute More Science jobs from Drug Discovery EVENT 20th International Symposium on Microsomes and Drug Oxidations (MDO) 22.05.14 Leinfelden-Echterdingen, Germany More science events from Careers Top Career snapshots archive Career snapshots feature people associated with drug discovery and drug development, with the aim of providing expert insights and advice on a wide range of positions and career paths in this field. Full Text Top Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant) For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our customer feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.